NCT00323739已完成2 期
Phase II Trial of Bevacizumab(Avastin) and RAD001(Everolimus)in the Treatment of Patients With Advanced Clear Cell Renal Carcinoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 80
- 试验地点
- 12
- 主要终点
- Progression Free Survival (PFS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Worsening of Their Disease
研究概览
简要总结
This phase II trial will evaluate the combination of bevacizumab + RAD001 in patients with metastatic renal cell carcinoma. In this trial the investigators will evaluate this combination in patients previously untreated with any anti-angiogenesis agent and patients who have previously received one prior regimen containing an anti-angiogenesis agent.
详细描述
All eligible patients will receive:
- Bevacizumab 10mg/kg, IV infusion, every 2 weeks
- RAD001 10 mg by mouth daily
All patients will be evaluated for response after completing two courses (8 weeks) of treatment. Patients with objective tumor response or stable disease will continue treatment with bevacizumab adn RAD001 on the same schedule. Treatment will continue until disease progression occurs.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically documented metastatic or unresectable locally recurrent clear cell renal carcinoma.
- •In patients with mixed histologies, the clear cell component must comprise ≥ 75% of the cancer
- •Previous nephrectomy is required with the following exceptions:
- •Primary tumor < 5cm
- •Extensive liver ( > 30% of liver parenchyma)or
- •Multiple (> 5) bone metastases, making nephrectomy a clinically contraindicated procedure
- •Patients may have had a maximum of 1 previous systemic regimen for metastatic disease
- •Patients may not have received previous bevacizumab. However, patients who have received other agents with anti-angiogenic activity (eg. sorafenib, SU11248, AG-013736, PTK787, thalidomide) as part of first-line treatment are eligible
- •Patients may not have received previous treatment with m-TOR inhibitors.
- •ECOG performance status 0 or 1
- •Measurable disease
- •Adequate liver, kidney and bone marrow function
- •No previous systemic treatment or radiation therapy for at least 2 weeks prior to study entry
- •Patients must be able to understand the nature of this study and give written informed consent
排除标准
- •Age < 18 years
- •Treatment with > 1 previous systemic regimen for metastatic renal carcinoma
- •History of acute myocardial infarction within 6 months
- •Clinically significant cardiovascular disease
- •History of stroke within 6 months
- •Patients with active brain metastases
- •Patients with meningeal metastases
- •Women who are pregnant or lactating
- •Patients who have been treated within 5 years for other invasive cancers
- •Patients with history or evidence by physical examination of CNS disease
- •Patients with clinical history of hemoptysis or hematemesis
- •Patients with history of deep vein thrombosis or thromboembolic disease requiring full dose anticoagulation
- •Patients with major surgical procedures, open biopsies, or significant traumatic injuries within 28 days or anticipated need for major surgical procedure during the course of the study
- •Patients with peg-tubes or G-tubes
- •Patients are ineligible if a fine needle aspiration biopsy has been performed within seven days
- •Patients with proteinuria
- •Patients with any non-healing wound, ulcer, or long-bone fracture
- •Patients with any history of a bleeding diathesis or coagulopathy
- •History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months
- •Patients who have received any other experimental drug within 28 days of starting treatment
- •History of any other severe and/or uncontrolled medical disease
- •History of HIV infection
- •Chronic treatment with steroids or other immunosuppressive agents
- •Patients with impaired GI function that compromises the ability to swallow or absorb RAD001
- •Patients who are unwilling or unable to comply with the protocol
研究组 & 干预措施
Bevacizumab and RAD001
Experimental
Bevacizumab 10mg/kg, IV infusion, every 2 weeks RAD001 10 mg by mouth daily
干预措施: bevacizumab (Drug)
Bevacizumab and RAD001
Experimental
Bevacizumab 10mg/kg, IV infusion, every 2 weeks RAD001 10 mg by mouth daily
干预措施: RAD001 (Drug)
结局指标
主要结局
Progression Free Survival (PFS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Worsening of Their Disease
时间窗: 18 months
次要结局
- Overall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death(18 months)
研究者
研究点 (12)
Loading locations...
相似试验
已完成
2 期
Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell CarcinomaKidney CancerRenal Cell CarcinomaNCT00113217M.D. Anderson Cancer Center52
已完成
2 期
A Study of Avastin (Bevacizumab) and Oxaliplatin Plus Xeloda (Capecitabine) in Patients With Advanced Colorectal Cancer.Colorectal CancerNCT01159171Hoffmann-La Roche50
已完成
2 期
Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube CancerFallopian Tube CancerOvarian CancerPrimary Peritoneal CarcinomaNCT01031381University of Pittsburgh50
已完成
2 期
Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation TherapyMetastatic CancerUnspecified Adult Solid Tumor, Protocol SpecificNCT01898130Northwestern University27
已完成
2 期
Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary SiteNeoplasms, Unknown PrimaryNCT00193622SCRI Development Innovations, LLC50